VIE News and Press, Viela Bio Inc. From 03/25/20

Viela Bio, Inc. (VIE) Q4 2019 Earnings Conference Call March 25, 2020 5:00 P.M. ET Company Participants Mitchell Chan - Chief Financial Officer Bing Yao - Chairman and Chief Executive Officer Jorn Drappa - Chief Medical Officer, Head of Research and Development Bill Ragatz - Vi...

The following slide deck was published by Viela Bio, Inc. in conjunction with their 2019 Q4 earnings Read more ...

VIELA BIO (NASDAQ: VIE ): FY GAAP EPS of -$7.02 misses by $5.15 . More news on: Viela Bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial results and provided program highlights for the fourth quarter and full year e...

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today announced it will host a webcast and conference call on Wednesday, March 25, 2020 at 5:00 p.m. ET ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen&#...

Initial public offerings offer public market investors the earliest chance to own a piece of a promising company. Capital-intensive fields like drug development have continued to witness a stream of IPOs -- some more successful than others. Besides raising cash for company operations, a public ...

Allakos (NASDAQ: ALLK ) resumed with Neutral rating and $94 (27% upside) at Goldman Sachs. More news on: Incyte Corporation, National Vision Holdings, Inc., Tandem Diabetes Care, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

The following slide deck was published by Viela Bio, Inc. in conjunction with this Read more ...

This year was another crucial one for biotech thanks in large part to initial public offerings (IPOs), merger and acquisition (M&A) activity and niche therapeutic areas garnering attention. During the year, while the number of IPOs slowed in comparison to last year, some of the largest M...